Legend Biotech $403 million follow-on offering
Davis Polk advised the underwriters in connection with the $403 million SEC-registered follow-on offering by Legend Biotech Corporation of 9,361,000 American depositary shares, each representing two ordinary shares, which included 1,221,000 ADSs sold pursuant to the underwriters’ over-allotment option. The ADSs are listed on the Nasdaq Global Select Market under the symbol “LEGN.”
Legend Biotech Corporation is primarily a global, clinical-stage biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, Legend Biotech Corporation is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor and natural killer cell-based immunotherapy.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Dennis Chu and Elizabeth Rodgers. Partner Lucy W. Farr and associates Bradford Sherman and Betsy Johnson provided tax advice. Partner David R. Bauer and associates David A. Frey and Adrian Rabin provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.